Abivax - ABVX Enterprise Value-to-Revenue Ratio

Public company logo of Abivax SA (ABVX)

ABIVAX attracts leading immunologists by providing them with robust financial support to combat inflammatory pathologies. The company is currently deploying capital toward research without having stable profit sources. This chart on GURU.Markets reflects the price-to-sales multiple, where the indicator level stands at 0.00, which is critical for assessing the potential for monopoly sales following FDA approval.

ABVX Abivax Corp: Company Value to Revenue in the range 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Abivax Corp (ABVX)

- current quotes and average value forecast:
Fundamental company valuation:ABVX - Abivax Corp
Mass-produced product of Abivax Pharma

ABIVAX is investing significant resources into R&D for RNA-based drugs to treat immunological diseases, making its market capitalization dependent on future successes. By analyzing the EV/Sales multiple, an investor assesses the total enterprise value, including debt, relative to revenue to determine the fairness of the asset's market price and the risks of hidden debt growth through the price action on the chart.

Competitor analysis for ABIVAX

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|Company Value to Revenue Ratio ADMA|Enterprise Value-to-Revenue Ratio protagonist-inc.com|Company Value to Revenue Immunovant, Inc. (IMVT)|EV/Sales Multiple KNSA|GRFS: Enterprise Value to Sales Volume|Adaptive Biotechnologies - Company Value to Revenue|CLDX: Company Value to Revenue Ratio|Aurinia Corp - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BioCryst Corp|VERA: EV/Sales Multiple|dianthustx.com (DNTH) - EV/Sales Multiple|PHVS (Pharvaris NV) - EV/Sales Multiple|ABCL: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tourmaline Bio, Inc. (TRML)|PGEN (Intrexon) - Business Value to Revenue|EV/Sales Multiple PHAR (Pharming Corp)|nektar.com (NKTR) - Enterprise Value-to-Revenue Multiple|UPB - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ZBIO (Zenas Biopharma)|IMNM: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gossamer Bio, Inc. (GOSS)|Enterprise Value-to-Revenue Ratio KalVista Pharmaceuticals|Septerna Inc (SEPN) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PVLA|SVRA (Savara) - Business Value to Revenue|Rigel Pharma - Company Value to Revenue|Total Company Value-to-Revenue Ratio AnaptysBio Corp (ANAB)|ATXS: Company Value to Revenue|Business Value to Revenue ENGN (enGene Holdings Inc.)|RAPT Therapeutics Inc. (RAPT) - Enterprise Value-to-Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - EV/Sales Multiple|ACRS (Aclaris Therapeutics, Inc) - EV/Sales Multiple|Kyverna (KYTX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple TLSA|Company Value to Revenue Cabaletta Bio, Inc. CABA|Ventyx Biosciences - Company Value to Revenue|THTX: Company Value to Revenue Ratio|AVTX - Enterprise Value-to-Revenue Ratio|ELDN: Enterprise Value-to-Revenue Ratio|Agenus Inc. (AGEN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Climb Bio Inc|ZURA (Zura Bio Ltd) - EV/Sales Multiple|EV/Sales Multiple aTyr Pharma Inc|EV/Sales Multiple ADAG|Total Company Value-to-Revenue Ratio ImageneBio|EV/Sales Multiple STTK (Shattuck Labs Inc)|EV/Sales Multiple Equillium, Inc. EQ|CNTB - Enterprise Value-to-Revenue Ratio|Immunic Therapeutics (IMUX) - Company Value to Revenue|ATRA: EV/Sales Multiple|InflaRx GmbH (IFRX) - EV/Sales Multiple|XFOR (x4pharma.com) - EV/Sales Multiple|EV/Sales Multiple Adicet Bio|Enterprise Value-to-Revenue Ratio Celularity Inc (CELU)|Company Value to Revenue INmune Bio Corp INMB|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD